Mercer Global Advisors
CRVS icon

Mercer Global Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Mercer Global Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,550
Closed -$10K – 1942
2023
Q1 		$10K Hold
10,550
– – ﹤0.01% 1914
2022
Q4 		$9K Hold
10,550
– – ﹤0.01% 1915
2022
Q3 		$9K Hold
10,550
– – ﹤0.01% 1806
2022
Q2 		$10K Hold
10,550
– – ﹤0.01% 1812
2022
Q1 		$17K Hold
10,550
– – ﹤0.01% 1857
2021
Q4 		$25K Buy
10,550
+50
+0.5% +$194 ﹤0.01% 1779
2021
Q3 		$51K Hold
10,500
– – ﹤0.01% 1720
2021
Q2 		$28K Hold
10,500
– – ﹤0.01% 1654
2021
Q1 		$32K Buy
+10,500
New +$37.9K ﹤0.01% 1595

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mercer Global Advisors's CRVS Position: Q2 2023 in Review

Mercer Global Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2023, closing a stake of 10,550 shares — an estimated $10K sold.

Mercer Global Advisors first reported a position in CRVS in Q1 2021 and held it in 9 quarters. The position peaked at $51K in Q3 2021. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2023.

  • Mercer Global Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Mercer Global Advisors sold 10,550 Corvus Pharmaceuticals shares in Q2 2023, an estimated $10K.
  • Mercer Global Advisors first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 9 quarters.
  • Mercer Global Advisors's Corvus Pharmaceuticals position peaked at $51K in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2023.

Based on Mercer Global Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.